Saturday, September 23, 2023
Saturday, September 23, 2023

iSTAR Medical Shows Initial Positive Progress of US STAR-V Trial for MINIject

iSTAR Medical, a medtech company delivering breakthrough eye care solutions to patients, today announced initial positive progress of MINIject™ in its US STAR-V trial. MINIject is a potentially best-in-class minimally-invasive glaucoma surgery (MIGS) implant and the only commercially available supraciliary MIGS device. The trial is now initiated in 13 sites across the US with positive feedback on initial implantations from world-leading glaucoma surgeons.

MINIject has demonstrated meaningful and enduring intraocular pressure (IOP) reduction, combined with a favorable safety profile, in completed and ongoing trials conducted in Europe, the Americas and Asia in over 150 patients so far.

The STAR-V trial is a US FDA-approved pivotal study assessing the safety and efficacy of MINIject in over 350 patients with primary open-angle glaucoma across the US, Canada and Europe. Following the trial’s FDA IDE approval in 2021, patient enrollment has been progressing as planned.

Glaucoma specialist Dr Steven D. Vold, from Vold Vision in Fayetteville, AR (USA), a long-standing contributor to ophthalmic device development and STAR-V trial investigator commented: “There is significant untapped potential in targeting the supraciliary space when leveraging MIGS to treat glaucoma, and MINIject enables this to be captured. iSTAR Medical’s approach uses its unique silicone micropore tissue friendly STAR material that enables biointegration. The supraciliary space has previously been demonstrated to be one of the most efficacious targets, and I am excited at the prospect of having a new MIGS approach with such strong potential to offer my patients.”

Dr Brian E. Flowers, a glaucoma specialist at Ophthalmology Associates at Fort Worth, TX (USA), and one of the investigators in STAR-V, said: “MINIject’s highly biocompatible anti-fibrotic technology enables safe and meaningful IOP reduction for patients, without compromising corneal health. Additionally, it doesn’t require a bleb, reducing post-implantation patient management and potential complications. Overall, based on my implantations to date, I am encouraged by MINIject’s potential to be a game-changing MIGS device in the stand alone setting to improve disease management and quality of life in glaucoma patients.”

Dr. William J. Flynn, MD, from Eye Associates Research in San Antonio, TX (USA), expressed: “Due to its promising powerful efficacy and safety, MINIject may open the door to treating a much larger patient population who previously couldn’t be treated by other MIGS devices. I am excited to be part of this trial and based on my positive experience thus far, I am optimistic for MINIject to be a valuable addition to our glaucoma treatment armamentarium.”

Michel Vanbrabant, CEO of iSTAR Medical, commented: “Following last year’s success with the approval of MINIject in Europe, we are excited to be progressing so positively in our pivotal approval trial in the United States. We remain very encouraged by the strong feedback from clinicians so far, and we are confident that our STAR-V trial will build on the safety and powerful efficacy outcomes demonstrated by MINIject in the STAR-I to STAR-IV trials.”


Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Lipogems® Announces 140 Independent Peer Reviewed Publications with 5 Years of Follow up in Orthopaedics

Giorgio Ninzoli, President of Lipogems International. "The gold standard for evidence is 1 year follow up and we are excited to report 5 years follow up with positive results after a single injection of MicroFat."

Stryker’s Triathlon Tritanium Baseplate Marks a Decade of Positive Patient Impact

Marking its 10th anniversary, the Triathlon Tritanium baseplate is designed with Stryker Orthopaedic Modeling and Analytics (SOMA) and enabled by Stryker's proprietary additive manufacturing technology.

Medtronic Diabetes Announces CE Mark for New Simplera™ CGM with Disposable All-in-one Design

The company's newest Simplera™ CGM is 50% smaller than its previous generation with a simple insertion and improved user experience

Study Outcomes Could Provide Insights Into New Targeted Treatments to Manage this Challenging Disease

The study aims to determine if immediate biological preservation of patient-derived chordoma tumor tissue, collected intraoperatively and implanted for serial sampling in translational research, will provide new insights into the biological weakness of the disease and contribute to developing improved treatment therapies reports NICO.

Henkel Joins with MedTech Europe to Drive Innovation In the Medical Technology Industry

Henkel has a long history of supporting the medical technology industry with its advanced adhesive and surface solutions. Through this, Henkel and MedTech Europe will collaborate on various initiatives such as supporting research and development projects, driving thought leadership and engaging in industry forums.

By using this website you agree to accept Medical Device News Magazine Privacy Policy